source
- Pfizer's experimental eczema drug tilrekimig shows strong skin clearance in Phase 2 trialPfizer reported that its three‑pronged antibody, tilrekimig, met the primary endpoint of its Phase 2 study in patients with moderate to severe atopic dermatitis. After 16 weeks, a significantly hig…
- Study finds GLP-1 weight-loss drugs appear safe and effective for children with severe obesityA transplant surgeon and obesity‑medicine specialist at NYU Langone reports that his research on GLP-1 weight‑loss drugs in children yields reassuring results. He notes that many of his transplant…